Accepted for/Published in: Journal of Medical Internet Research
Date Submitted: Oct 8, 2018
Open Peer Review Period: Oct 9, 2018 - Oct 17, 2018
Date Accepted: Nov 20, 2018
(closed for review but you can still tweet)
A systematic review of decision-support tools for regenerative medicine
ABSTRACT
Background:
Decisional tools or decision-support tools are tools that can be used to support complex decision making and problem-solving. Since their advent in the 1970s, these tools have been used to support evidence-based decision-making in various industries, including healthcare, agriculture and the environment.
Objective:
The review aims to provide a systematic update of the regenerative medicine decision-support tool landscape, with a focus on tissue engineering, cell and gene therapies, to identify the gaps in literature and inform future development of decisional tools in the area.
Methods:
This systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. As the review only used publicly available information, an ethics review board approval was not required.
Results:
Article identification from database searches identified 646 articles for review. At screening stage, 13 were deemed relevant for full text eligibility assessment. The small identification of initial articles and the small number post screening indicates the novelty of this research area.
Conclusions:
This study systematically reviewed the decisional tool landscape for regenerative medicine. Current studies have largely addressed the manufacturing challenges and cost reduction drivers for allogeneic cell therapies. Decisional tools in tissue engineering and gene therapies are lacking. To more comprehensively understand the overall costs and supply chain robustness of these life-saving cell therapies, the entire process from tissue procurement to post-administration should be considered. In order to put forward industrially relevant decisional tools, costs and process assumptions must be industrially validated to ensure any results derived from the model to be useful and relevant. Future decisional tools to integrate the different facets of currently available decisional tools should be developed in order to inform decision-making in the rapidly expanding and transformative regenerative medicine field. Clinical Trial: N/A
Citation
Per the author's request the PDF is not available.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.